Intestinal peptide transporters, including hPEPT1, facilitate the absorption of cephalosporins and angiotensinconverting enzyme inhibitors, and have been investigated as a means to improve oral drug absorption. Renal peptide transporters including hPEPT2, may also facilitate renal reabsorption of such compounds. In vitro and animal studies suggest that co-administration of peptidomimetic compounds may alter oral pharmacokinetics, although this has not been well studied in humans. The purpose of this study was to determine whether co-administration of the hPEPT substrates captopril and cephradine alters the oral pharmacokinetics of either agent. Nine healthy male volunteers received a single oral 25-mg dose of captopril, a single oral 500-mg dose of cephradine, or concurrent ingestion of captopril and cephradine in a cross-over manner. Venous blood samples were taken and captopril and cephradine pharmacokinetics were determined using noncompartmental analyses. No significant differences were observed in captopril or cephradine pharmacokinetics when administered together as compared to each agent alone (a marginal decrease in C max was observed for both captopril and cephradine during co-administration [5-15%]; however, differences were not statistically significant). The results of our study suggest that hPEPT1 and hPEPT2 are unlikely to contribute to clinically important drug interactions in humans.
T he disposition of many xenobiotics is highly dependent on the activity of intestinal mucosal transporters. 1 Efflux transporters have been studied extensively, and can limit the systemic availability of a large range of compounds. 2, 3 In contrast, the role of nutrient transporters in facilitating drug absorption and tissue delivery has been investigated less comprehensively. It is well recognized, however, that multiple nutrient transporter systems involved in the active absorption of peptides, glucose and other carbohydrates, amino acids, organic anions, organic cations, bile acids, and other nutrients are abundant in the intestinal mucosa, and that many of these transporters may also affect the absorption of exogenously administered xenobiotics. 1, [4] [5] [6] In the small intestine, di-and tripeptides are absorbed through carrier-mediated processes by peptide transporters, including the human oligopeptide transporter, hPEPT1 (SLC15A1). hPEPT1 is an H + / peptide symporter located in the brush border membrane of the small intestine which has broad substrate specificity. 1, 7, 8 In addition to transporting oligopeptides, hPEPT1 also mediates the membrane transport of a diverse range of xenobiotics, including peptidomimetic drugs. Substrates for hPEPT1 include β-lactam antibiotics, aminocephalosporins with a free α-amino group, antiviral prodrugs (eg, valacyclovir, valgancyclovir), and angiotensinconverting enzyme (ACE) inhibitors. [8] [9] [10] Peptide transporters are also present in other organs such as the kidneys, central nervous system, and respiratory tract. [11] [12] [13] The presence of hPEPT1 and the related renal oligopeptide transporter, hPEPT2, in the kidneys may play a role in the renal reabsorption of peptidomimetics. [14] [15] [16] Drug interactions occurring as a result of coadministration of hPEPT1 substrates in humans are not well studied. These interactions are of interest, because there are a large number of hPEPT1 drug substrates, and hPEPT1 is actively targeted as a means to improve oral drug absorption. Therefore, it would be desirable if co-administration of hPEPT1 substrates did not result in interactions. However, co-administration of transporter substrates may result in competition for transporters, and could affect the intestinal absorption and disposition of the substrates. To this end, competitive inhibition of hPEPT1-mediated transport of substrates, including cephalosporin antibiotics and ACE inhibitors, has been described in cultured epithelial cell models, excised membrane vesicles, and in situ animal models. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Similarly, competitive inhibition of peptide transport has been demonstrated in renal brush border membrane vesicles, and suggested in animal models. 15 Based on these data, one may anticipate that drug-drug and/or drug-nutrient interactions involving peptide transporters are possible in humans. The purpose of this study was to assess the potential interaction between 2 peptidomimetic hPEPT1 substrates, the aminocephalosporin cephradine, and the ACE inhibitor captopril, in humans. Specifically, we hypothesized that competition of captopril and cephradine for intestinal transporters may result in impaired and/or delayed absorption of either or both agents.
METHODS

Human Subjects
Nine healthy male volunteers were included in this study. Subjects were deemed healthy by physical examination and serum chemistries. The mean weight of the subjects was 75 kg (range, 64-91 kg), and all subjects were within 20% of their ideal body weight. The mean age of the subjects was 26 years (range, 20-32 years). All subjects were nonsmokers, had refrained from other medications (prescription and over-the-counter) for 1 week before study entry, and had no history of hypersensitivity to cephalosporins or ACE inhibitors. All subjects provided written informed consent before participation, and all procedures were approved by the University of Michigan Institutional Review Board before initiating the study.
A randomized, open label, 3-way, cross-over design was used. The 3 study phases consisted of: (1) Phase A: a single 25-mg oral dose of captopril (Capoten, Bristol-Myers Squibb, New York, NY); (2) Phase B: a 500-mg oral dose of cephradine (Velosef, Bristol-Myers Squibb, New York, NY) coadministered with a 25-mg oral dose of captopril, and (3) Phase C: a single 500-mg oral dose of cephradine. All medications were from the same lot. In each phase, subjects were instructed to fast overnight (approximately 10 hours) before oral administration of the assigned study drug treatment, which was administered with 240 mL of water. During each phase, subjects were required to remain in a sitting position for 4 hours after receiving the study medication. Each study phase was separated by a minimum of 2 weeks. Standard meals were provided 4 and 9 hours after dosing. Venous blood samples (10 mL) were collected immediately before dosing, and at 0.25. 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 9, and 10 hours after drug administration during each treatment phase. Samples were centrifuged at 4 ο C, and the plasma samples for captopril assays were treated with excess n-ethylmaleimide (NEM) to form a stable captopril-NEM adduct and then stored at -20 ο C until time of analysis.
Analytical Methods
After an oral dose, captopril is present in the plasma as unchanged drug (approximately 50% of dose) and a dimeric disulfide metabolite (approximately 10% of dose). Therefore, plasma concentrations of both total and unchanged captopril were determined as described previously, with some minor modifications. 29, 30 In brief, the 4-ethoxy proline analogue of captopril served as the internal standard. After extracting the excess NEM with 5 mL of ethyl acetate, the aqueous phase was acidified with 500 µL of 2M HCl, to which 2 g of sodium chloride was added, vortexed and extracted with 10 mL of purified ethyl acetate. The ethyl acetate layer was evaporated to dryness under nitrogen in a 40-50 ο C water bath. The dry extract was treated with 100 µL of hexafluoro-2-propanol and 50 µL of trifluoroacetic anhydride for 15 minutes at 60 ο C, evaporated under N 2 and the dry residue reconstituted with ethylacetate: N-methyl formamide (1:1). An aliquot containing the hexafluorisopropyl esters of the NEM adducts of captopril and the internal standard was injected into a gas chromatography-mass spectrophotometer assembly. To determine total captopril content, tributylphosphine (20% v/v) was added to the plasma samples, vortexed and heated for 60 minutes at 50
Excess tributylphosphine was extracted with 5 mL of ethyl acetate. Subsequently 0.2 mL of NEM (10 mg/mL) was added to the aqueous plasma layer which was then allowed to stand for 15 minutes at room temperature. Further extraction, derivatization and GC analysis were performed as outlined for unchanged captopril. Standard curves were prepared daily and constructed from spiked blank plasma containing 0-500 ng/mL of captopril, 500 ng of internal standard and 100 µL of NEM. For this assay, the lower limit of detection of captopril in plasma was 2 ng/mL, and the inter-day coefficient of variation was 7%.
Cephradine concentrations were determined using high-performance liquid chromatography using methods adapted from Lidgren and colleagues. 31 Briefly, the analytical column was a µBondpak C18 column, the mobile phase was 13% acetonitrile in 0.02 M NaH 2 PO 4 (pH 5), the flow rate of the mobile phase was 1.6 mL/min, and absorbance was measured at 262 nm. For the cepharadine assay, the intra-day coefficient of variation for the assay was <6% over the concentration range of 3 to 20 µg/mL, and the inter-day coefficient of variation was <5% over the same concentration range.
Pharmacokinetic Analysis
Conventional noncompartmental pharmacokinetic analyses were performed. 32 Maximum plasma concentration (C max ), and time to maximum plasma concentration (T max ), were determined by visual inspection of the data. The apparent elimination constant (k e ) was calculated based on linear regression of the log-linear terminal phase of the plasma concentration time curve. Elimination half-life was determined as (ln 2/k e ). The area under the plasma concentration versus time curve (AUC inf ) was calculated using the trapezoidal rule and extrapolated to infinity based on C n /k e , were C n is the last measureable concentration. Additionally, partial areas under the plasma concentration versus time curve in the first hour after administration (AUC 0-1 ) were calculated to better characterize changes in absorption (ie, while absorption was the dominant process).
Statistical Analyses
Statistical analyses were performed to explore potential differences in pharmacokinetic parameters between study phases using 2-tailed, paired t tests. Data are presented as mean ± standard deviation (SD). For all tests, P < .05 was considered to be significant.
RESULTS
Noncompartmental Analyses
Mean plasma concentrations of unchanged and total captopril versus time curves after oral administration of captopril alone or after co-administration of cephradine with captopril to human subjects are shown in Figure 1 . The relevant pharmacokinetic parameters for unchanged and total captopril during phase A (captopril alone) and Phase B (captopril coadministered with cephradine) are summarized in Table I . No significant differences were noted in the pharmacokinetics of either unchanged or total captopril when administered alone or in combination with cephradine. Of interest, the C max for both unchanged and total captopril was slightly decreased when captopril was co-administered with cephradine as compared to when it was administered alone and likewise the T max was slightly delayed. Detectible total captopril concentrations were still present at the end of the sampling (10 hours); our sampling strategy captured 89.1% of the mean AUC 0-infinity for total captopril alone, and 88.1% of the mean AUC 0-infinity for total captopril with cephradine.
Cephradine mean plasma concentration versus time curves are similar after oral administration of cephradine alone or after co-administration of cephradine with captopril ( Figure 2) . The pharmacokinetic parameters for cephradine when administered alone (phase C) or in combination with captopril are listed in Table II . Captopril administration resulted in a marginal decrease in the C max of cephradine; the mean percent decrease in C max was 10.0 ± 15.6, although this difference only approached significance (P = .053). Figure 3 shows the effects of captopril administration on cephradine C max for individual subjects. In 6 of the 9 subjects, captopril administration was associated with a decrease in cephradine C max , whereas cephradine C max was higher with co-administration of captopril in 3 subjects. Co-administration of captopril did not significantly delay cephradine absorption, nor did it significantly impair the extent of cephradine absorption, as indicated by T max , f (0-1), and AUC inf values (Table II) .
DISCUSSION
The oligopeptide transporter hPEPT1 plays a role in the active absorption of several drugs, and has been suggested as a potential means to improve the oral absorption of drugs in the drug design process. Despite the pharmacological importance of hPEPT1, little is known about the propensity of hPEPT1 (and the related renal transporter, hPEPT2) to cause drug interactions in humans. In this study, we observed no clinically significant interaction when 2 peptidomimetic substrates, captopril and cephradine, were co-administered to healthy human subjects by means of the oral route. Co-administration slightly decreased the mean peak plasma concentration of cephradine, however, this difference only approached statistical significance. Although this could indicate competition for uptake by peptide transporters in the intestine, no other pharmacokinetic parameters supported such an interaction; specifically, no significant changes in T max , AUC inf , or partial AUC's were observed with captopril co-administration. Both captopril and cephradine are eliminated, at least in part, by the kidneys through glomerular filtration and tubular secretion. 33, 34 Although competition for renal re-absorption by means of renal transporters (eg, hPEPT1 and hPEPT2) could increase the renal clearance of the substrates when co-administered, there was no evidence of this in the present study.
Our hypothesis, that cephradine and captopril may compete for peptide transporters, was based on several prior observations. Cephradine is transported by means of hPEPT1 in cultured human intestinal cell monolayers, a process that is inhibited by oligopeptides and peptidomimetics. 19, 24, 35 Intestinal perfusion studies in animals and studies using isolated intestinal membrane vesicles have demonstrated that ACE inhibitors are also transported by means of peptide transporters, and that their transport is competitively inhibited by oligopeptides and peptidomimetics, including cephalosporins. [20] [21] [22] Similarly, in vitro investigations have described the saturable transport of ACE inhibitors by the renal peptide transporters hPEPT1 and hPEPT2.
14 Jacolot and colleagues demonstrated that intra-intestinal administration of captopril in rats causes a marked increase in the half-life of the cephalosporin cefdinir. 36 In a subsequent experiment, the same group administered cephalexin (a cephalosporin) and quinapril (an ACE inhibitor) to rats, using different routes of administration (ie, oral and parenteral administration). They found that while parenteral administration of quinapril did not alter the disposition of either orally or parenterally administered cephalexin, the co-administration of oral cephalexin and oral quinapril resulted in a 30% decrease in cephalexin oral clearance and a 30% increase in cephalexin AUC. 37 They also observed a decrease in the cephalexin absorption rate constant with oral quinapril, but no difference in the extent of absorption. They suggested that competition of cephalosporins and ACE inhibitors for active tubular secretion in the kidneys by means of a renal anionic transport system, as well as inhibition of active transport of cephalexin by quinapril in the intestine may be responsible for the observed pharmacokinetic behavior. 16, 38, 39 Despite in vitro and animal studies suggesting the possibility of a significant interaction between cephradine and captopril, there are several plausible explanations for the lack of such an interaction in the current study. Based on the variability in our data, the number of subjects required to detect a 30% decrease in total captopril AUC when coadministered with cephradine is 8 (with a power of 80% and α = .05). The corresponding sample size calculation to detect a 30% decrease in cephradine AUC when coadministered with captopril is 9. Therefore, we believe our study was adequately powered to detect what we consider clinically important differences. Although total captopril concentrations were still detectible in plasma samples at the end of our sampling strategy (10 hours), we do not believe this affected our ability to detect a potential interaction, as the primary mechanism of a potential interaction is likely to involve changes in absorption, which would be characterized by our sampling. Moreover, our sampling captured almost 90% of the total captopril AUC. Importantly, it is likely that multiple mechanisms are responsible for cephradine and captopril absorption in vivo, so that inhibition of a single route of permeation or single transporter (or even a single family of transporters), has a diluted effect. This phenomenon likely includes both active and passive transport mechanisms. For example, we demonstrated that the in vivo intestinal permeability of valacyclovir, a well known hPEPT1 substrate, correlates well with the intestinal expression of the transporter, HPT1, whereas correlation with hPEPT1 is poor. 40 The role of HPT1 in the transport of other hPEPT1 substrates is currently under investigation; however, it is reasonable to speculate that there is inherent redundancy in peptide transporters. In this regard, it is interesting to note a recent study conducted to examine the potential for cephalexinvalacyclovir interactions in human subjects after oral co-administration of valacyclovir and cephalexin. The authors reported that co-administration of valacyclovir and cephalexin minimally affected the AUC of the parent drug acyclovir, suggesting minimal interaction between these hPEPT1 substrates. 41 The authors indicate that the lack of interaction may suggest the possibility that cephalexin and valacyclovir are absorbed by means of other transporters and are less dependent on hPEPT1-mediated transport than previously suggested. 41 It is also pertinent to note that transporter expression and distribution may be quite different in humans compared with animals and in vitro models.
Another factor that could explain the lack of interaction between cephradine and captopril is that the doses used may have been insufficient to saturate the existing transporters in vivo. The doses were chosen based on typical clinical doses of the 2 drugs. However, the Michaelis-Menton constants (k m ) for cephradine and captopril absorption have been reported as 1.50 mM and 5.91 mM, respectively. 42 Although it is difficult to accurately estimate the precise volume in which an oral dosage form would be dissolved in vivo, the 500-mg dose of cephradine and the 25-mg dose of captopril corresponds to molar amounts of approximately 1.43 and 0.12 mmol, respectively. It is therefore quite possible that the concentrations of the drugs present in the intestinal lumen may have been substantially lower than those required to saturate the peptide transportermediated absorption process. Study drugs were administered in the fasted state, without standardization of prior dietary protein intake. Theoretically, this may have influenced our results. For example, studies conducted in rats indicate fasting for 24-48 hours may increase intestinal PEPT1 expression; it is unknown, however, whether this phenomenon occurs in humans, and, if so, whether the brief fast used in the present study (10 hours) would sufficiently impact hPEPT1 expression. 43, 44 Additionally, animal studies have suggested that high protein diets may result in increased expression of PEPT1, although this finding has not yet been confirmed in humans. [45] [46] [47] The drugs used in this study, cephradine and captopril were not chosen because of any perceived likelihood that these compounds would be commonly coadministered clinically; rather, they were selected as representative substrates for aminocephalosporins and ACE inhibitors, respectively. To this end, captopril and cephradine are both well characterized PEPT1 substrates that have been shown to compete for PEPT1 (in both in vitro and animal experiments). 48, 49 Captopril also offered a practical advantage over other ACE inhibitors, because of its relatively short half-life (ie, this may limit the duration of any hypotensive effects in study subjects). It is unknown whether choosing alternative ACE inhibitor and cephalosporin substrates would produce similar results.
CONCLUSIONS
To the best of our knowledge, this is the first study examining the potential interaction between cephalosporins and ACE inhibitors in humans. In summary, co-administration of 2 peptidomimetic compounds, cephradine and captopril, did not result in clinically significant changes in the pharmacokinetics of cephradine or captopril, despite sharing common transport pathways in the small intestine and kidneys. Based on these results, co-administration of these hPEPT1 and hPEPT2 substrates is not likely to result in clinically important drug interactions; although it is unknown whether this conclusion can be generalized to other hPEPT1/hPEPT2 substrates, other studies support this premise. This apparent lack of propensity for transport-related drug interactions offers further support for the use of hPEPT1-mediated transport as a means of improving oral drug absorption.
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